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Abstract
Mitochondria play important roles in cellular energy metabolism, free radical generation, and
apoptosis. Defects in mitochondrial function have long been suspected to contribute to the
development and progression of cancer. In this review article, we aim to provide a brief summary
of our current understanding of mitochondrial genetics and biology, review the mtDNA alterations
reported in various types of cancer, and offer some perspective as to the emergence of mtDNA
mutations, their functional consequences in cancer development, and therapeutic implications.
Introduction
Mitochondrial defects have long been suspected to play
an important role in the development and progression of
cancer. Over 70 years ago, Warburg pioneered the research
on mitochondrial respiration alterations in the context of
cancer and proposed a mechanism to explain how they
evolve during the carcinogenic process [1,2]. In his series
of landmark publications, he hypothesized that a key
event in carcinogenesis involved the development of an
"injury" to the respiratory machinery, resulting in com-
pensatory increases in glycolytic ATP production. Eventu-
ally, malignant cells would satisfy their energy needs by
producing a large portion of their ATP through glycolytic
mechanisms rather than through oxidative phosphoryla-
tion. Due to the inherent inefficiency of glycolytic ATP
generation, this represents a somewhat unique metabolic
state of the malignant cells and would require high con-
sumption of glucose to fulfill cellular energy require-
ments. This is in contrast to many normal cells, which use
oxidative phosphorylation as the preferred means of ATP
generation with high efficiency. The differences in energy
metabolism between normal and cancer cells constitute a
biochemical basis to speculate that therapeutic strategies
might be developed to selectively kill cancer cells due to
their inherently compromised respiratory state [1–3].
Since the initial publications by Warburg over half a cen-
tury ago, a number of cancer-related mitochondrial de-
fects have been identified and described in the literature.
These defects include altered expression and activity of
respiratory chain subunits and glycolytic enzymes, de-
creased oxidation of NADH-linked substrates, as well as
mitochondrial DNA (mtDNA) mutations. While there are
many reports of these phenomena, the mechanisms re-
sponsible for the initiation and evolution of mtDNA mu-
tations, and their roles in the development of cancer, drug
resistance, and disease progression still remain to be elu-
cidated. This review article provides a brief summary of
our current understanding of mitochondrial genetics and
biological function, reviews the reported mtDNA altera-
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tions in human malignancies, and discusses possible
mechanisms by which mtDNA mutations emerge in can-
cer cells and their clinical relevance.
Key aspects of mitochondrial biology and genet-
ics
Mitochondria are semi-autonomous organelles that per-
form essential functions in cellular metabolism and the
regulation of cell death. While the exact origin of mito-
chondria is still uncertain, it is widely believed that they
arose from an endosymbiotic relationship between a gly-
colytic proto-eukaryotic cell and an oxidative bacterium
[4–6]. Mitochondria possess a double-membrane struc-
ture and contain their own genome along with their own
transcription, translation, and protein assembly machin-
ery. As such, they are able to maintain genomic independ-
ence from the nucleus. However, as a consequence of
proto-mitochondrial genes integrating into the nuclear
genome throughout evolution, most mitochondrial pro-
teins are encoded by nuclear DNA (nDNA) and imported
into mitochondria. Although the replication of mitochon-
drial DNA (mtDNA) is not synchronized with nDNA rep-
lication, the overall number of mitochondria per cell
remains fairly constant for specific cell types during prolif-
eration, suggesting that the generation of mitochondria is
largely influenced by extra-mitochondrial signal transduc-
tion events. This conclusion is further supported by the
observation that mitochondrial biosynthesis continues
even when mtDNA is deleted. Thus, the replication of mi-
tochondria does not require the presence of mtDNA.
Energy and metabolism
The most well-known and best-characterized function of
mitochondria is the production of adenosine triphos-
phate (ATP) through oxidative phosphorylation. This
process is accomplished by a series of protein complexes,
collectively known as the respiratory chain, encoded by
both nDNA and mtDNA. The complete respiratory chain
contains at least 87 polypeptides, 13 of which are encoded
by mtDNA. Hence, the majority of the respiratory chain
components are nuclear-encoded and imported into mi-
tochondria after their translation in the cytosol (Figure 1).
Thus, oxidative phosphorylation is a unique biochemical
process achieved by a well-coordinated effort of the pro-
tein products from two separate genomes (nuclear and
mitochondrial) working in concert within the same cells.
However, this process is not absolutely required to fulfill
cellular energy requirements. Glycolysis can also generate
ATP and provides a compensatory mechanism when oxi-
dative phosphorylation becomes inefficient as a conse-
quence of defects in the respiratory chain.
It is important to note that as electrons are transported
through the respiratory chain during mitochondrial respi-
ration, some of the electrons may escape or leak from elec-
tron transport complexes and react with molecular oxygen
to form superoxide radicals (O2
-). This diversion or bifur-
cation of electron flow occurs mainly at complexes I and
III [7,8]. It is reasonable to assume that certain mtDNA
mutations may cause an alteration of the electron trans-
port components that compromises the normal electron
flow. This can lead to an increase of bifurcation and gen-
eration of superoxide radicals, which are subsequently
converted into other reactive oxygen species (ROS). In
fact, mitochondrial DNA mutations [summarized in this
review] and increased oxidative stress [for a review see [9]]
have been observed in various types of cancer cells in sev-
eral independent studies. However, the direct link be-
tween mtDNA mutations and the increase of ROS
generation in cancer cells has not been demonstrated ex-
perimentally.
In addition to their critical role in the fulfillment of cellu-
lar energy (ATP) requirements, mitochondria are also es-
sential in the processing of important metabolic
intermediates for various pathways involved in the metab-
olism of carbohydrates, amino acids, and fatty acids. The
tricarboxylic acid cycle in the mitochondrial matrix is a
prime example of a biochemical pathway where many im-
portant metabolic intermediates converge [10,11]. A ma-
jor portion of the urea cycle is also compartmentalized
within the mitochondria where metabolic processing of
nitrogen-containing amino acid intermediates occurs
[12]. Fatty acids are broken down into two-carbon units
by a series of β-oxidations and further processed to acetyl
CoA in the mitochondrial matrix. Thus, while the genera-
tion of ATP via oxidative phosphorylation represents an
important, but not essential mitochondrial function, mi-
tochondria are indispensable to eukaryotic cells due to
their extensive involvement in other critical metabolic
processes. This may explain why ρ0 cells, in which the
mtDNA is deleted [13], continue to maintain mitochon-
drial mass without the mtDNA-encoded respiratory pro-
tein components.
Apoptosis and cell survival
During the past decade, the most significant research ad-
vance in mitochondrial biology may be the discovery that
mitochondria play an important role in apoptosis, a fun-
damental biological process by which cells die in a well-
controlled or programmed manner. Several nDNA-encod-
ed pro-apoptotic proteins including cytochrome c, apop-
tosis inducing factor (AIF), endonuclease G, and smac/
DIABLO normally reside in the mitochondria where they
perform known or yet unidentified physiological func-
tions. However, once these protein factors are released
from mitochondria, they trigger a series of biochemical
events leading to activation of apoptotic signaling cas-
cades [for a review see [14]]. Perhaps the most well char-
acterized apoptotic cascade is the activation of caspases (aMolecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/9
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class of proteases) by cytochrome c and apaf-1 in the pres-
ence of ATP or dATP [15]. In contrast, translocation of AIF
from mitochondria to the nucleus appears to cause apop-
tosis in a caspase-independent manner [16]. Because ap-
optosis plays a critical role in cancer development and in
the cellular response to anticancer agents, the significance
of mtDNA mutations in cancer is obviously an important
area of current investigation. However, the exact role of
mtDNA mutations in the cellular apoptotic response to
anticancer agents has not been defined. Several groups
have used respiration-deficient ρ0 cells lacking mtDNA to
evaluate the role of respiration in drug sensitivity, achiev-
ing various results. For instance, Singh et al reported that
ρ0 cells were resistant to adriamycin and photodynamic
therapy, whereas these cells were equally sensitive to
alkylating agents and γ-radiation as compared with their
parental cells with respiration-competent mitochondria
[17]. A study by Cai et al demonstrated that cytochrome c
release and caspase activation in response to stau-
rosporine treatment were maintained in ρ0 cells. Howev-
er, unlike the case with ρ+ cells, in which a dramatic
oxidation of intracellular glutathione (GSH) occurred fol-
lowing cytochrome c release, the thiol-disulfide redox
state in apoptotic ρ0 cells was relatively unchanged. Thus,
mitochondrial signaling of caspase activation can be sep-
arated from its bioenergetic function [18]. In contrast,
Figure 1
The mitochondrial electron transport chain complexes are encoded by two genetic systems: the mitochondrial DNA
(mtDNA) and the nuclear DNA (nDNA). The mtDNA codes for 7 NADH dehydrogenase (ND) subunits for complex I, a
cytochrome b for complex III, 3 cytochrome c oxidase (COX) subunits for complex IV, and 2 ATPase (ATPase6/8) for com-
plex V. Complex II is solely encoded by nDNA. The solid arrows indicate the direction of electron flow in the respiration
chain; dashed arrows indicate the flow of genetic information from mtDNA or nDNA to RNA to protein; the numbers indicate
the actual number of protein subunits coded by each genetic system. Specific inhibitors of RNA transcription or protein trans-
lation with relative selectivity for each genetic system are indicated in blue.
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Joshi et al reported that a functioning mitochondrial res-
piratory chain was required for cellular sensitivity to
BMD188, a novel prostate cancer chemotherapeutic [19].
The varying reports regarding the sensitivity of ρ0 cells to
apoptosis induction are likely a reflection of the different
mechanisms of action of the various stimuli in question.
In addition to alterations in sensitivity to anticancer
agents, ρ0 cells derived from human solid tumor cell lines
have been shown to lose their capacity for anchorage-in-
dependent growth and tumorigenicity when injected into
nude mice [20]. Both of these properties were restored
when the ρ0 cells were fused with cells containing normal
mitochondria, indicating that mtDNA is required to
maintain a cancer phenotype. Other studies have shown
that while ρ0 cells lose their capacity for anchorage-inde-
pendent growth, they maintain their tumorigenicity in
nude mice [21]. The conflicting results observed in ρ0 cells
may indicate a complex interaction between the nuclear
and mitochondrial genomes in transformation. Lack of
tumorigenicity in some ρ0 cells may be a reflection of in-
sufficient changes in nuclear-encoded genes to maintain
tumorigenicity, whereas the tumorigenicity of other ρ0
cells may be a consequence of additional transforming
events. It should be emphasized that although ρ0 cells rep-
resent a valuable in vitro experimental model system to in-
vestigate the role of mitochondrial respiration in drug
sensitivity, their clinical relevance is uncertain. While ma-
lignant cells are often characterized by mtDNA mutations
and partial deletions, their mtDNA is unlikely to be com-
pletely deleted. As such, cells carrying different known
mtDNA mutations represent a more appropriate model
system for the investigation of the effects of mtDNA mu-
tations on cellular sensitivity to anti-cancer agents.
Genetics and mutations
The human mitochondrial genome has been completely
sequenced and each gene contained within it has been
identified and characterized [22,23]. The human mtDNA
is a supercoiled, double-stranded circular molecule of
16,569 base pairs in size. As mentioned earlier, it codes
for 13 of the 87 proteins required for oxidative phospho-
rylation as well as the 12S and 16S rRNAs and 22 tRNAs
required for protein synthesis in the mitochondria (Figure
1). It is of interest to note that other than the aforemen-
tioned 13 respiratory chain components, no other genes
for structural proteins are found in human mtDNA. It is
believed that the early mitochondrial genome derived
from symbiotic bacteria in proto-eukaryotic cells may
have contained other genes, which may have been lost or
integrated into the nuclear DNA during evolution. One
interesting example is that the nuclear-coded mitochon-
drial enzyme superoxide dismutase (SOD2) is more ho-
mologous to the bacterial SOD than to the eukaryotic
cytosolic isozyme (SOD1). In fact, mtDNA migrates into
the nucleus at a much higher frequency than nuclear DNA
integrates into mitochondria [24,25]. The retention of
genes coding only for the respiratory chain components in
the mitochondrial genome is likely the consequence of a
selection process rather than a random event, although
the underlying mechanism remains unclear.
Each mitochondrion contains 2–10 copies of its genome.
Although the number of mitochondria per cell varies with
cell type, an individual cell typically contains a fairly con-
stant copy number of mtDNA. During fertilization, the
mitochondria are transmitted through the oocyte's cyto-
plasm. Thus, the mitochondrial genome is distinct from
the nuclear genome in that it follows a strict maternal in-
heritance pattern [For a more in-depth review refer to [26–
28]]. Within a cell, mtDNA replication is semi-autono-
mous and is not synchronized with the S phase of the cell
cycle. However, the two genetic systems (nuclear and mi-
tochondrial) appear to be closely coordinated by yet un-
known mechanisms. The overall biogenesis of
mitochondria keeps pace with cell proliferation and cell
growth.
Although the mitochondrion contains the necessary ma-
chinery to express its genome, many of its protein compo-
nents are encoded by nuclear DNA. It should be noted
that mitochondrial RNA transcription can be preferential-
ly inhibited by ethidium, whereas transcription of RNA
from nDNA is preferentially inhibited by α-amanitin.
Likewise, protein synthesis in mitochondria is sensitive to
inhibition by tetracycline and chloramphenicol, whereas
cytosolic protein synthesis is selectively inhibited by cy-
cloheximide (Figure 1). This differential sensitivity to met-
abolic inhibitors further supports the hypothesis that
mitochondria originated from bacteria. This also provides
a basis for using these metabolic inhibitors as important
tools to investigate the interaction between the two genet-
ic systems.
Another feature that distinguishes the mitochondrial and
nuclear genomes is their inherent susceptibilities to dam-
age. It is known that mtDNA is far more vulnerable to mu-
tations than nuclear DNA due to its lack of histone
protection, limited repair capacity, and close proximity to
the electron transport chain, which constantly generates
superoxide radicals. Considering mtDNA lacks introns,
most mutations occur in the coding sequences and are
thus, likely to be of biological consequence [29]. Howev-
er, there may be intracellular mechanisms that offset some
of the effects of mtDNA mutations. Recombination of
mtDNA molecules between fused mitochondria has been
well-established in yeast and plant cells [30,31]. In spite
of this, this phenomenon had not been demonstrated in
mammalian cells until recently, probably because the
mtDNA sequence of individuals tends to be relatively uni-Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/9
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form due to its maternal inheritance pattern. Ono et al
isolated two types of respiration-deficient cell lines with
pathogenic mtDNA mutations from patients with mito-
chondrial diseases. Generation of hybrids via fusion with
normal cells was able to restore morphology and respira-
tory enzyme activity, indicating the exchange of genetic
contents between the mitochondria. The authors pro-
posed that this may represent a mechanism to defend
against mitochondrial dysfunction caused by the accrual
of mtDNA lesions with age [32]. It is likely that this proc-
ess is also relevant in the context of cancer and other dis-
eases and serves to provide a buffering capacity to
maintain mitochondrial function in the presence of mtD-
NA mutations.
Because each cell contains many mitochondria with mul-
tiple copies of mtDNA, it is possible that wild-type and
mutant mtDNA can co-exist in a state called heteroplas-
my. During cell division, mitochondria are randomly dis-
tributed to daughter cells. Over time, the proportion of
the mutant mtDNA within the cell can vary and may drift
toward predominantly mutant or wild type to achieve
homoplasmy. Thus, the biological impact of a given mu-
tation may vary, depending on the proportion of mutant
mtDNAs carried by the individual. This effect contributes
to the various phenotypes observed amongst family mem-
bers carrying the same pathogenic mtDNA mutation. So-
matic mutations in mtDNA and their potential clinical
implications will be further discussed below.
Mitochondrial DNA alterations in cancer
Mutations in mtDNA have been identified in various
types of human cancer. Additional file 1 provides a sum-
mary of mutations found in the non-coding region and
coding regions of the mtDNA in cancer cells (see Addi-
tional file 1).
Breast cancer
Comprehensive studies examining mtDNA mutations in
breast cancer have been published recently. A study by
Tan et al used a combination of temporal temperature gel
electrophoresis and direct DNA sequencing to screen the
complete mitochondrial genome for mutations in 19 sets
of paired normal and tumor tissues from the same pa-
tients. Somatic mutations were identified in 14 of the 19
patients (74%). The bulk of the mutations (81.5%) were
restricted to the D-loop region. However, mutations were
also detected in the 16S rRNA, ND2, and ATPase 6 genes
[33]. In another study, the investigators analyzed fine nee-
dle aspirates of primary breast tumors and matched lym-
phocytes of 18 patients. As observed in the
aforementioned study, somatic mutations were detected
in the majority of the patients (61%) and most of the mu-
tations identified were in the D-loop region. The remain-
ing mutations were found in the ND1, ND4, ND5, and
Cytochrome b genes [34]. Earlier studies also revealed
point mutations and deletions in breast tumors. The 4977
bp common deletion was found in malignant and normal
breast tissue of a smaller number of patients with abnor-
malities of the breast [35]. In addition to mutations, ele-
vated expression of cytochrome c oxidase II mRNA was
also detected in breast tumors in a number of patients as
compared to the normal tissue [36].
Ovarian cancer
Liu et al analyzed mtDNA from matched normal and ma-
lignant ovarian tissue samples obtained from 10 patients
with ovarian carcinomas. A PCR-based method was used
to sequence the complete mitochondrial genome in both
sets of tissues. Comparison of the DNA sequences ob-
tained from the tumor and normal tissues enabled the
identification of somatic mtDNA mutations. This study
revealed a high incidence (60%) of somatic mutations in
the tumor tissues examined. Most of the identified muta-
tions were T -> C or G -> A transitions. The somatic muta-
tions were restricted to 4 regions of the mitochondrial
genome: the D-loop, 12S  rRNA, 16S  rRNA, and cyto-
chrome b. The authors speculated that these regions may
represent mutational hotspots in ovarian cancer [37].
Colorectal cancer
The integrity of the mitochondrial genome has been ex-
amined in several colorectal cancer cell lines as well as in
primary patient tissues. One study [38] examined normal
and malignant colon cells from 10 individuals using a
PCR-based method to sequence the entire mitochondrial
genome. 7 of 10 patients had somatic mtDNA mutations.
The mutations were found in the 12S rRNA, 16S rRNA,
ND1, ND4L, ND5, Cytochrome b, COXI, COXII, and
COXIII genes. The majority of the mutations were transi-
tions with the exception of one insertion. Somatic muta-
tions in the non-coding D-loop region have also been
identified in colon cancer patients. Somatic A -> T and G -
> C transitions and deletions were detected using a com-
bination of heteroduplex analysis and single-stranded
conformation polymorphism (SSCP) analysis [39]. Addi-
tionally, alterations in the expression of mitochondrial-
encoded respiratory chain subunits have been detected in
primary tumor samples from colorectal cancer patients as
well as patients with pre-malignant familial polyposis coli
(FPC) syndrome. A study utilizing tissues from 15 color-
ectal cancer patients found that ND2 mRNA levels were el-
evated in the malignant tissue as compared to normal
tissue from the same individuals [40]. Elevated expression
of ND1 mRNA and 16S rRNA was also detected in the pol-
yps of FPC patients as compared to normal colon tissue
[41]. Analysis of the mitochondrial genome in colorectal
cancer cell lines also revealed abnormalities. Elevated ex-
pression of 16S rRNA, ND4, ND4L, cytochrome b, COXII,
ATPase 6, and ATPase 8 was detected in the HT-29 cell lineMolecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/9
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[42]. Another study examining the Caco-2 cell line detect-
ed mtDNA deletions [43]. Other investigators have evalu-
ated a link between mitochondrial microsatellite
instability and cancer. Analysis of 45 sporadic colorectal
cancers using PCR-SSCP detected microsatellite altera-
tions involving insertion or deletion of a cytidine in a
polycytidine tract in the D-loop region in 44% of the ex-
amined cases. The authors also identified frame shift mu-
tations in ND1 and ND5. Some of the detected alterations
were heteroplasmic, while others where homoplasmic.
No large-scale deletions were found [44,45].
Gastric cancer
PCR-SSCP was utilized to examine nuclear microsatellite
instability, mtDNA large deletions, and mtDNA muta-
tions in one study of 32 gastric carcinomas. Surprisingly,
nuclear microsatellite instability was not correlated with
the presence of mtDNA mutations or deletions in the
specimens examined. This observation suggests a possibil-
ity that the nucleus and mitochondria may use different
repair mechanisms to repair DNA damage. The common
deletion of mtDNA was detected in 54% of cases, and
mtDNA mutations were identified in 44% of cases, sug-
gesting that major mtDNA alterations tend to be associat-
ed with gastric cancer. Most of the mutations
corresponded to insertions/deletions in the D-loop region
or transitions in ND1, ND5, and COXI [46]. Earlier stud-
ies revealed the presence of mutations in the D-loop of
both non-malignant and malignant gastric tumors
[47,48].
Hepatic cancer
An analysis of 19 tumors from patients with hepatocellu-
lar carcinoma (HCC) indicated that mutations in the D-
loop were a frequent event and could be used as a molec-
ular tool for the determination of clonality [49]. Somatic
mtDNA mutations were identified in a separate study in
both the malignant and non-malignant liver tissue of
HCC patients. The frequency of mutations was correlated
with the degree of malignancy [50]. An earlier study exam-
ining hepatic tumors found that mtDNA deletions were
present in the cirrhotic liver tissue surrounding the tu-
mors, but not in the tumors themselves [51]. Further stud-
ies are required to clearly determine if mtDNA mutations
are correlated with malignant transformation.
Esophageal cancer
Two recent reports investigated the frequency of D-loop
mutations in esophageal cancer. One group focused on
adenocarcinomas of Barrett's esophagus. In that study, D-
loop alterations were identified in 40% of the patients ex-
amined [52]. The other study showed that D-loop muta-
tions were much less frequent in esophageal cancer,
occurring in only 5% of specimens analyzed [53]. Clearly,
analysis of mtDNA from more esophageal tumor samples
is needed in order to determine the frequency of D-loop
mutations and their relevance in this cancer type.
Pancreatic cancer
An investigation of 15 pancreatic cancer cell lines and xe-
nografts by Jones et al revealed mtDNA alterations in
nearly every case. The mutations were identified in several
different genes including 12S rRNA, 16S rRNA, ND1,
ND2, COXI, COXII, ATPase 6, COXIII, ND4, ND4L, ND5,
ND6, Cyt b, as well as the non-coding D-loop region. The
authors also found a 6-fold to 8-fold increase in the mtD-
NA mass in the tumor cells as compared to normal pan-
creatic cells. The very high frequency of mtDNA mutations
and the increase of mtDNA contents in pancreatic cancer
cells led the authors to speculate that mtDNA may serve as
a diagnostic tool [54]. It is not clear if the increase of mtD-
NA mass reflects an increased replication of mtDNA in re-
sponse to defective mtDNA function due to extensive
mutations.
Renal cell carcinoma
A well-characterized alteration of mtDNA associated with
renal cell carcinoma (RCC) is a 264-bp deletion of the
ND1 gene. This deletion eliminates 264 nucleotides of the
mitochondrial genome between nucleotide positions
3323 and 3588 [55]. A separate study reported the loss of
mtDNA and mRNA coding for subunit the ND3 gene
[56]. Alterations in the expression of both mitochondrial
and nuclear-encoded protein components of the respira-
tory chain have also been observed in renal cell carcino-
ma. The earlier study revealed that the steady-state
transcript levels of all mitochondrial-encoded subunits
were strikingly lower than in the corresponding normal
renal tissue. In contrast, the levels of nuclear-encoded res-
piratory chain subunits were higher than in the normal
controls [57]. A more recent study that examined tumor
samples from 25 RCC patients demonstrated that mito-
chondrial enzyme and DNA contents of all tumors dif-
fered significantly from normal tissue. However, the
authors found that decreased content of respiratory chain
subunits rather than alterations in mtDNA content corre-
lated with tumor aggressiveness. In particular, nearly all
tumors lost ATP synthase activity in Complex V [58]. Their
data supports the hypothesis that decreased capacity for
oxidative phosphorylation and increased glycolysis may
favor tumor growth and invasiveness.
Prostate cancer
Until recently, there were no reports of mtDNA alterations
in prostate cancer. Two recent studies suggest that mtDNA
mutations and deletions may play a role in prostate car-
cinogenesis. The first study examined mtDNA deletions in
34 malignant prostate specimens. The entire mtDNA was
amplified using long distance PCR. Electrophoresis was
used to visualize alterations in the mtDNA size due to de-Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/9
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letions. The authors found that the average number of de-
letions increased with advanced age [59]. In the other
study, however, Jeronimo et al sequenced the D-loop re-
gion, 16S rRNA, and NADH subunits in matched prema-
lignant prostate lesions, primary prostate tumors, and
normal lymphocytes from 16 patients. Mutations were
identified in 3/16 patients. In spite of the relatively infre-
quent incidence of mutations, the mutations were found
to occur early in disease progression and were detectable
in bodily fluids during the early stages of the disease [60].
Brain tumors
Malignant glioma is the best-characterized type of brain
tumor with respect to mtDNA alterations. The most fre-
quent observation involves changes in the copy number
of mtDNA. A study that examined 45 glioma specimens
found that mtDNA was highly amplified in 87% of the
cases. The authors also examined a nuclear-encoded gene
that is frequently amplified in human cancers as a refer-
ence. They found that the erb-b gene copy number in-
creased in only 18% of the tumor specimens, indicating
the mtDNA alterations may be much more frequent than
those of nuclear-encoded genes in malignant gliomas
[61]. A separate study of 15 tumor sections confirmed the
high frequency of mtDNA copy number changes [62]. In-
terestingly, the authors also detected a transfer of mtDNA
to the nucleus, and showed that the nuclear localization
of the mtDNA segment was correlated with the increase of
mtDNA copy numbers. It has been proposed that mtDNA
integration into the nuclear genome may represent a
mechanism of oncogene activation [63]. A later study of
astrocytic tumors indicated that the heteroplasmy of a
well-characterized polymorphic site in the D-loop region
was lost in the tumor specimens, but not in the normal
brain tissue references [64]. Clearly, mtDNA alterations
are a frequent event in the development and progression
of brain tumors and are worthy of further investigation.
Thyroid cancer
It has been known for more than 2 decades that thyroid
tumors contain abnormally high numbers of mitochon-
dria [65]. More recent studies have indicated that mtDNA
alterations are present in thyroid cancer cells. An examina-
tion of 21 thyroid tumors using two-dimensional gene
scanning revealed that somatic mutations were present in
23% of analyzed specimens. The majority of the muta-
tions that were found occurred in the genes coding for
subunits of complex I of the respiratory chain. Their find-
ings indicate that somatic mtDNA mutations may be in-
volved in thyroid tumorigenesis and that accumulation of
certain mutations may play a role in tumor progression
[66]. A more recent study of 79 thyroid tumors reported
that the mtDNA common deletion was identified in
100% of Hürthle cell tumors (n = 43), 33.3% of adenom-
as (n = 15), and in 18.8% of non-Hürthle cell papillary
carcinomas. A number of somatic point mutations in
mtDNA were also identified in the tumor tissues, especial-
ly in Hürthle cell tumors. The authors concluded that
mtDNA alterations in the genes coding for Complex I and
Complex IV of the respiratory chain may contribute to the
development of thyroid tumors. Germline polymor-
phisms of the ATPase 6 gene were correlated with the oc-
currence of the mtDNA common deletion, which appears
to be a hallmark of Hürthle cell tumors [67].
Other solid tumors
The frequency and types of mtDNA alterations in other
solid tumors have not been as well characterized com-
pared to the aforementioned cancer types. There are a lim-
ited number of reports regarding mtDNA mutations in
solid tumors of the bladder, head and neck, and lung
[68,69]. In general, there appear to be two features of
mtDNA alterations in cancer irrespective of tumor type.
First, the majority of mutations are base transitions from
T to C and G to A. Second, while there is diversity in the
individual genes in which mutations occur, the D-loop re-
gion seems to be the most frequent site of somatic muta-
tions across most tumor types. A more thorough analysis
is required in order to determine the functional signifi-
cance of specific mtDNA alterations and their role in can-
cer development.
Hematologic malignancies
Alterations in mtDNA in hematologic malignancies have
been reported by several groups. The first hematologic
mtDNA abnormalities were discovered by Clayton et al in
1967 using cesium chloride-ethidium density cetrifuga-
tion and electron microscopy to examine the structure of
mtDNA in leukemic leukocytes. The authors identified al-
ternate mtDNA structures comprised of circular dimers,
catenated dimers, and catenated trimers. While these al-
ternate mtDNA structures can also exist in normal cells,
the authors found an unusually high percentage of them
in leukemic cells as compared to normal controls [70]. In
a follow-up study, the authors examined the leukocytes of
14 patients with acute and chronic granulocytic leukemi-
as. Circular dimers were found in all 14 patients, but not
in leukocytes from 3 healthy donors. It was also noted
that the percentage of circular dimers decreased in some
leukemic patients following chemotherapeutic treatment,
suggesting that the severity of leukemia may be related to
the presence of circular dimers [71]. The decrease of circu-
lar mtDNA dimers after chemotherapy also suggests a pos-
sibility that the leukemia cells containing this mtDNA
abnormality may be more vulnerable to elimination by
therapeutic agents.
Analysis of mtDNA from acute myelogenous leukemia
(AML) cells revealed that the origins of abnormal mtDNA
structures could be traced back to the bone marrow [72].Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/9
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A separate study in leukemia cells from patients with acute
lymphoblastic leukemia (ALL) identified mtDNA point
mutations in 11 of the 30 patients [73]. Mutations of
mtDNA have also been identified in patients with myelo-
dysplastic syndrome (MDS). Gattermann et al described
mutations in cytochrome b, cytochrome c oxidases I and
II and ATPase 8 in MDS cells [74,75]. The more recent
study further confirmed the increased mutations in the
mitochondrially-encoded COX I and COX II genes [76].
Interestingly, it has also been shown that increased mtD-
NA content and alterations in the expression of the mtD-
NA-encoded electron transport subunits may occur in the
absence of mtDNA mutations. For instance, Jia et al
showed that CEM/VLB100 cells expressing MDR-1 con-
tained significantly higher mtDNA content than the pa-
rental CEM cells which lack MDR-1. In spite of this
increase in mtDNA content, the authors did not find a cor-
responding increase in mitochondrial protein or lipid lev-
els. However, it was noted that ATP generation was
enhanced and proliferation was significantly decreased in
the MDR-1 expressing cells as compared to parental CEM
cells [77]. Another study examining doxorubicin-resist-
ant, MDR-1 positive K562 cells found decreased expres-
sion of COX I and II and increased expression of COXIII.
These alterations in COX expression levels were not relat-
ed to mtDNA mutations or changes in transcription rates
[78]. MtDNA amplification in the absence of mtDNA mu-
tations has been reported in patients with acute myeloid
leukemia [79]. Finally, while mtDNA alterations in hu-
man lymphomas have not been reported, studies in
murine lymphoma showed that the expression of ND5
was increased in a metastatic variant of RAW 117-H10
large cell lymphoma. It is hypothesized that the increased
expression of ND5 may play a role in tumor metastasis
[80,81].
Research perspectives and implications
Mitochondria possess their own genome which codes for
13 of the 87 proteins required for oxidative phosphoryla-
tion as well as the 12S and 16S rRNAs and 22 tRNAs nec-
essary for protein synthesis in the mitochondria [26–28].
Mutations and alterations in mitochondrial DNA have
been shown to play an important role in certain diseases
such as Leber's hereditary optic neuropathy, maternally
inherited diabetes melittus, and Leigh's syndrome [82].
While these diseases of the mtDNA are due to germline
mutations, somatic mutations have been observed in oth-
er diseases, especially in cancer. Given the substantial role
of mitochondria in ATP metabolism, in generation of free
radicals, and in regulation of apoptosis, mutations in
mtDNA are likely to affect cellular energy capacities, in-
crease oxidative stress, cause ROS-mediated damage to
DNA, and alter the cellular response to apoptosis induc-
tion by anticancer agents as indicated in this review and
others [83,84]. Thus, the role of mtDNA mutations in can-
cer development, genetic instability and disease progres-
sion, and the development of drug resistance warrants a
comprehensive investigation in the future. Furthermore,
the high frequency of mtDNA alterations in cancer and
their presence in the early stages of disease could possibly
be exploited as clinical markers for early cancer detection
[85].
The existence of multiple mitochondria with many copies
of mtDNA in a cell presents a unique situation and a chal-
lenge for investigating mtDNA mutations and their func-
tional consequences. Analysis of germline homoplasmic
mutations (a mutation present in all copies of mtDNA in
cells from an individual) is relatively simple and can be
achieved using straightforward laboratory techniques.
However, it is possible that the wild-type and mutant
mtDNA may co-exist in a state known as heteroplasmy.
This is particularly important in somatic mutations rele-
vant to cancer. Detection of heteroplasmic mtDNA muta-
tions and their evolution during cancer development
requires special techniques and careful consideration.
Both homoplasmic and heteroplasmic mutations have
been observed in cancer cells. The mechanisms by which
homoplasmy arises from heteroplasmic mutations in can-
cer cells still remain to be defined. A recent study by Coller
et al using extensive computer modeling suggests that if a
mtDNA mutation occurs in a tumor progenitor cell,
homoplasmy can be achieved entirely by chance through
unbiased mtDNA replication and sorting during cell divi-
sion without selection for physiological advantage [86].
However, considering the fact that mtDNA lacks sizeable
introns, mutations in the coding sequences have a high
probability of changing the amino acid composition of
the encoded proteins. Thus, many of the mtDNA muta-
tions are likely to have physiological consequences and
would confer a cellular advantage or disadvantage in
growth and survival. Figure 2 schematically illustrates
some possible mechanisms by which heteroplasmic mu-
tations may emerge and evolve with various outcomes.
Somatic mtDNA mutations can be induced by various
DNA-damaging agents, including endogenous mitochon-
drial ROS and/or certain anticancer drugs and radiation
(step 1). The lack of histone protection, limited repair
ability, and close proximity to the electron transport chain
make mtDNA far more susceptible to DNA-damaging
agents. Since such induced mutation does not involve all
copies of mtDNA, the initial mutation is heteroplasmic
with the mutated mtDNA being the minority. If a muta-
tion leads to a disadvantage in cell growth or survival,
such mutation is deemed to diminish (step 2). Converse-
ly, if a mutation confers cell growth/survival advantage or
facilitates mtDNA replication, such a mutation is likely to
survive the selection and emerge as a heteroplasmic muta-
tion (steps 3 and 4). Depending on the duration and theMolecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/9
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degree of growth/survival advantage, the cells carrying the
"advantageous" mtDNA mutation may eventually be-
come dominant and evolve to establish a homoplasmic
mutant state (step 5). A growth/survival advantage may
also be acquired through a second event such as addition-
al DNA alterations caused by ROS (step 6). It is possible
that mtDNA mutations may cause a functional change of
the affected protein (subunit of the electron transport
complexes) in such a way that it compromises the efficien-
cy of the electron transport chain, leading to electron flow
bifurcation and increased generation of ROS (step 7). A
moderate increase of ROS has been found to stimulate cel-
lular proliferation and mitochondrial biogenesis [87,88].
The increase in endogenous ROS thus provides a constant
stimulus for cell proliferation, and most importantly, may
cause further damage to both mtDNA and nDNA, leading
to cancer development, genetic instability, and disease
progression (step 8). Further investigations are needed to
test this hypothesis. Future studies using both experimen-
tal model systems in the laboratory and primary cancer
specimens from patients in a sequential manner are likely
to provide critical information.
Cancer cells are generally more active than normal cells in
metabolic ROS generation and are constantly under oxi-
dative stress [for a review see [9]]. It is conceivable that
certain mtDNA mutations may be caused by endogenous
ROS in cancer cells. Mutations in mtDNA could in turn
cause further increases of ROS production by the mecha-
nism discussed above, leading to more mutations and ad-
ditional oxidative stress. Studies in our laboratory have
demonstrated that primary leukemia cells from patients
with chronic lymphocytic leukemia contain significantly
higher levels of cellular ROS compared to normal lym-
Figure 2
Schematic illustration of somatic mtDNA mutation. Mitochondrial DNA mutations can be induced by endogenous or exoge-
nous DNA-damaging agents such as ROS, chemical agents, and radiation. The numbered arrows indicate possible outcomes of
mtDNA mutations including heteroplasmic and homoplasmic states. See text for detail.
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phocytes [89]. The ROS levels are especially high in CLL
cells from patients who have had prior chemotherapy.
Chemotherapeutic agents have been shown to accumu-
late in mitochondria and damage mtDNA [90,91]. It is
possible that some of the mtDNA mutations identified in
cancer cells are the result of treatment with chemothera-
peutic agents. Such somatic mutations would likely
emerge as heteroplasmic mutations and might eventually
become homoplasmic with time due to clonal expansion
if they confer replication and survival advantages. Analy-
sis of mtDNA mutations in these leukemia samples and
evaluation of their correlation with cellular ROS contents
are important to test this possibility.
Given the critical role of mitochondria in apoptosis, it is
conceivable that mutations in mtDNA in cancer cells
could significantly affect the cellular apoptotic response to
anticancer agents. As discussed above, experiments with
ρ0 cells lacking mtDNA to evaluate the role of respiration
in drug sensitivity produced various results. This may re-
flect complex interactions between ρ0 cells and anticancer
agents with different mechanisms of action. Evaluating
changes in drug sensitivity in cancer cells bearing mtDNA
mutations would be even more complicated, since differ-
ent mtDNA mutations are likely to have varying effects on
the apoptotic response. However, the clonal selection/ex-
pansion hypothesis would predict that the mutations re-
covered from cancer cells that survive chemotherapy are
likely to be associated with resistance to the particular
drugs used in prior therapy. Furthermore, certain mtDNA
mutations in cancer cells are likely to cause malfunctions
of the respiratory chain and increase free radical genera-
tion. This biochemical change provides an unique oppor-
tunity to selectively kill this population of cancer cells by
using agents that inhibit free radical elimination and
cause further ROS accumulation, leading to lethal damage
in the cancer cells [92]. Taken together, it is evident that
mtDNA mutations are clinically relevant and have poten-
tial therapeutic implications.
Conclusion
In summary, the presence of mtDNA mutations in cancer
cells is consistent with the intrinsic susceptibility of mtD-
NA to damage and constitutive oxidative stress. Altera-
tions in respiratory activity and mtDNA abnormalities
appear to be a general feature of malignant cells. Muta-
tions and deletions in mtDNA and abnormal expression
of mtDNA-encoded proteins have been observed in vari-
ous solid tumors and hematological malignancies. How-
ever, studies to date have focused on identification and
characterization of the altered mtDNA, with only limited
insight into functional consequences and clinical rele-
vance. Future research to address the functional aspects of
mtDNA mutations in cancer development and therapeu-
tic response is likely to be fruitful and have significant
clinical implications in the prevention and treatment of
cancer. Important questions to be addressed include (1)
What is the exact role of mtDNA in cancer initiation and
progression? (2) How do heteroplasmic mtDNA muta-
tions arise and evolve to a homoplasmic state in cancer
cells? (3) Is there a mechanistic link between mtDNA mu-
tations, changes in respiration and ROS generation, and
alterations in apoptosis? (4) What are the most important
mtDNA mutations that confer drug resistance and
growth/metastasis advantage in clinically relevant cancer
cells? (5) How can we effectively kill those cancer cells
that carry mtDNA mutations and become resistant to con-
ventional anticancer agents? The answers to these ques-
tions would undoubtedly advance our understanding of
mitochondrial biology in cancer, as well as provide a basis
for designing new strategies for effective cancer preven-
tion, diagnosis, and treatment.
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